Real-world outcomes in patients with non-small cell lung cancer with EGFR exon 20 insertion mutations receiving mobocertinib

被引：1

作者：

Mok, T. S. K. ^{[1
]}

Liu, G. ^{[2
]}

Nyaw, S. F. ^{[3
]}

Curcio, H. ^{[4
]}

Cortot, A. ^{[5
]}

Kam, T. Y. ^{[6
]}

Descourt, R. ^{[7
]}

Chik, Y. K. ^{[8
]}

Cheema, P. K. ^{[9
]}

Gwinnutt, J. M. ^{[10
]}

Churchill, E. N. ^{[11
]}

Nyborn, J. ^{[12
]}

Curran, E. ^{[13
]}

Yin, Y. ^{[14
]}

Chong, K. ^{[15
]}

Tanaka-Chambers, Y. ^{[16
]}

Kretz, J. ^{[17
]}

Cadranel, J. ^{[18
,19
]}

机构：

[1] Chinese Univ Hong Kong, Prince Wales Hosp, Dept Clin Oncol, Hong Kong, Peoples R China

[2] Princess Margaret Canc Ctr, Ontario Canc Inst, Med Oncol, Toronto, ON, Canada

[3] Tuen Mun Hosp, Dept Clin Oncol, Hong Kong, Peoples R China

[4] Ctr Francois Baclesse, Oncol Dept, Caen, France

[5] CHRU Lille, Dept Thorac Oncol, Lille, France

[6] Pamela Youde Nethersole Eastern Hosp Main Block, Dept Clin Oncol, Hong Kong, Peoples R China

[7] CHU Brest, Oncol Dept, Hop Morvan, Brest, France

[8] Queen Elizabeth Hosp QEH, Dept Clin Oncol, Hong Kong, Peoples R China

[9] Univ Toronto, William Osler Hlth Syst, Oncol, Brampton, ON, Canada

[10] IQVIA, Global Epidemiol, Reading, Berks, England

[11] Takeda Pharmaceut USA Inc, Global Med Affairs Oncol, Lexington, MA USA

[12] Takeda Dev Ctr Amer Inc, Global Med Affairs Oncol, Cambridge, MA USA

[13] Takeda Dev Ctr Amer Inc, Global Evidence & Outcome Res, Lexington, MA USA

[14] Takeda Dev Ctr Amer Inc, Observat Res Analyt, Lexington, MA USA

[15] Takeda Dev Ctr Amer Inc, Clin Data Management, Cambridge, MA USA

[16] Takeda Pharmaceut, Stat & Quantitat Sci, Cambridge, MA USA

[17] Takeda Pharmaceut Int AG, Dept Thorac Oncol, Glattpark Opfikon, Zurich, Switzerland

[18] Hop Tenon, AP HP, Pulmonol & Thorac Oncol Dept, Paris, France

[19] Sorbonne Univ Paris, Paris, France

来源：

ANNALS OF ONCOLOGY | 2023年 / 34卷

关键词：

D O I：

10.1016/j.annonc.2023.10.663

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

585P

引用

页码：S1698 / S1699

页数：2

共 50 条

[41] Epidemiological characteristics and therapeutic advances of EGFR exon 20 insertion mutations in non-small cell lung cancer
Pan, Binyang
Liang, Jiaqi
Shi, Haochun
Rao, Kungeng
Guo, Weigang
Zhan, Cheng
THORACIC CANCER, 2023, 14 (33) : 3247 - 3258
[42] EGFR Exon 18 Mutations in Advanced Non-Small Cell Lung Cancer: A Real-World Study on Diverse Treatment Patterns and Clinical Outcomes
Xu, Haiyan
Yang, Guangjian
Li, Weihua
Li, Junling
Hao, Xuezhi
Xing, Puyuan
Yang, Yaning
Wang, Yan
FRONTIERS IN ONCOLOGY, 2021, 11
[43] Osimertinib treatment for patients with EGFR exon 20 insertion positive non-small cell lung cancer
van Veggel, B.
van der Wekken, A.
Hashemi, S.
Cornelissen, R.
Monkhorst, K.
Heideman, D.
Radonic, T.
Smit, E. F.
Schuuring, E.
De Langen, J.
ANNALS OF ONCOLOGY, 2018, 29
[44] Sensitivity to Immune Checkpoint Blockade in Advanced Non-Small Cell Lung Cancer Patients with EGFR Exon 20 Insertion Mutations
Metro, Giulio
Baglivo, Sara
Bellezza, Guido
Mandarano, Martina
Gili, Alessio
Marchetti, Giovanni
Toraldo, Marco
Molica, Carmen
Reda, Maria Sole
Tofanetti, Francesca Romana
Siggillino, Annamaria
Prosperi, Enrico
Giglietti, Antonella
Di Girolamo, Bruna
Garaffa, Miriam
Marasciulo, Francesca
Minotti, Vincenzo
Gunnellini, Marco
Guida, Annalisa
Sassi, Monica
Sidoni, Angelo
Roila, Fausto
Ludovini, Vienna
GENES, 2021, 12 (05)
[45] FDA Approval Summary: Amivantamab for the Treatment of Patients with Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
Chon, Katie
Larkins, Erin
Chatterjee, Somak
Mishra-Kalyani, Pallavi S.
Aungst, Stephanie
Wearne, Emily
Subramaniam, Sriram
Li, Yangbing
Liu, Jiang
Sun, Jielin
Charlab, Rosane
Zhao, Hong
Saritas-Yildirim, Banu
Bikkavilli, Rama Kamesh
Ghosh, Soma
Philip, Reena
Beaver, Julia A.
Singh, Harpreet
CLINICAL CANCER RESEARCH, 2023, 29 (17) : 3262 - 3266
[46] Osimertinib for Chinese advanced non-small cell lung cancer patients harboring diverse EGFR exon 20 insertion mutations
Yang, Guang-Jian
Li, Jun
Xu, Hai-Yan
Sun, Yang
Liu, Liu
Li, Hong-Shuai
Yang, Lu
Zhang, Yuan
Li, Guo-Hui
Wang, Yan
LUNG CANCER, 2021, 152 : 39 - 48
[47] Clinico-genomic Characteristics of Patients with Non-small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations
Okahisa, M.
Udagawa, H.
Matsumoto, S.
Kato, T.
Oizumi, S.
Furuya, N.
Hayakawa, D.
Toyozawa, R.
Nishiyama, A.
Ohashi, K.
Miyamoto, S.
Nishino, K.
Oi, H.
Sakai, T.
Shibata, Y.
Izumi, H.
Sugiyama, E.
Nosaki, K.
Zenke, Y.
Yoh, K.
Goto, K.
JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S455 - S456
[48] Sunvozertinib, a Selective EGFR Inhibitor for Previously Treated Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
Wang, Mengzhao
Yang, James Chih-Hsin
Mitchell, Paul L.
Fang, Jian
Camidge, D. Ross
Nian, Weiqi
Chiu, Chao-Hua
Zhou, Jianying
Zhao, Yanqiu
Su, Wu-Chou
Yang, Tsung-Ying
Zhu, Viola W.
Millward, Michael
Fan, Yun
Huang, Wen-Tsung
Cheng, Ying
Jiang, Liyan
Brungs, Daniel
Bazhenova, Lyudmila
Lee, Chee Khoon
Gao, Bo
Xu, Yan
Hsu, Wei-Hsun
Zheng, Li
Janne, Pasi A.
CANCER DISCOVERY, 2022, 12 (07) : 1676 - 1689
[49] Clinical characteristics and efficacy in non-small cell lung cancer patients with EGFR exon 20 insertion and EGFR amplification
Gao, X.
Wei, X-W.
Wu, Y-L.
Zhou, Q.
ANNALS OF ONCOLOGY, 2019, 30
[50] PRO-CTCAE Analysis of Mobocertinib in EGFR Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer (NSCLC)
Garcia Campelo, M. R.
Zhou, C.
Ramalingam, S. S.
Lin, H. M.
Kim, T. M.
Riely, G. J.
Mekhail, T.
Nguyen, D.
Biber, J.
Romero, H.
Goodman, E.
Popat, S.
Janne, P. A.
JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S487 - S488

← 1 2 3 4 5 →